Navigation Links
Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
Date:11/4/2008

CALGARY, Nov. 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has made a decision to pursue a pivotal (Phase II/III) randomized trial using the combination of REOLYSIN(R) with paclitaxel/carboplatin in refractory patients with head and neck cancers. The decision was made following a review of results by the Company's Board of Directors from the Company's ongoing U.K. Phase I and Phase II combination REOLYSIN(R) and paclitaxel/carboplatin clinical trials. The results were presented November 1, 2008 at the International Society for Biological Therapy of Cancer (iSBTc) annual meeting in San Diego, CA.

"Eight out of nine head and neck patients reported on to date from the Phase I and Phase II studies had either a partial response or stabilization of disease," said Dr. Brad Thompson, President and CEO of Oncolytics, "This response rate exceeds that of the current standard of care for this patient group, and more than warrants proceeding to a pivotal program."

Oncolytics is currently convening a group of experts in Europe and the U.S. to design a protocol for the Phase II/III trial, which will then be submitted to the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMEA) for review. Following FDA and EMEA review, Oncolytics expects to file for approval for this trial early in 2009.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-look
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Clinical Update Conference Call
2. Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
3. Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
4. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
5. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
6. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
7. Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting
8. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008
9. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
10. Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale
11. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Inc. (Nasdaq: OSTE ), a leader in ... healing, announced today that it has submitted a ... Drug Administration (FDA) to obtain marketing clearance for ... repair or replace the dura mater (the outermost ... procedures. This filing is based, in part, ...
(Date:12/17/2009)... /PRNewswire-Asia/ -- Using a novel stem cell based,technology ... eliminate a glioma -- brain cancer -- of ... in Beijing. The treatment shows that the activated,immune ... well as cancer daughter,cells. The amazing outcome of ... Cellonis that the future vaccination therapies may be,targeted ...
(Date:12/17/2009)... rise the U.S. in November, even as the overall unemployment rate ... in the pharmaceutical industry. , ... (Vocus) December 17, ... job losses - which is to say, there were no ... area was related to the Pfizer acquisition of Wyeth. Meanwhile, healthcare ...
(Date:12/17/2009)... the Daveys, the GLOBALS, ,and PM360 Pharma Choice Awards Programs. ... ... -- Chicago-based full-service healthcare communications agency Goble & Associates, Inc. ... honoring exceptional creative and interactive work. , , ,THE RX ... Awards of Excellence for the following creative work: Hospira LifeShield ...
Breaking Biology Technology:Osteotech Submits 510(k) Application to FDA for Clearance of its Duratech(TM) BioRegeneration Matrix 2Osteotech Submits 510(k) Application to FDA for Clearance of its Duratech(TM) BioRegeneration Matrix 3For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 2For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 3For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing 4The MedZilla Report for November 2009 - Healthcare Employment Up, And No Major Bad News for Pharma, Either 2The MedZilla Report for November 2009 - Healthcare Employment Up, And No Major Bad News for Pharma, Either 3Goble & Associates Creative Work Awarded at Advertising Industry Competitions 2Goble & Associates Creative Work Awarded at Advertising Industry Competitions 3Goble & Associates Creative Work Awarded at Advertising Industry Competitions 4
... 7 - Decision Taken to Advance ... ThromboGenics NV (Euronext Brussels: THR), a biotechnology company,focused ... Exchange: BINV), announce today that they have,successfully completed ... first Phase I trial of TB-402, which is ...
... Globally, approximately 418 billion,people are currently infected with ... hepatitis in the 21st century cannot be,understated or ... by Kalorama Information. Paradoxically, despite the obvious ... to contain hepatitis. Yet the incidence and,prevalence of ...
... N.J., Sept. 6 Pharmasset, Inc.,(Nasdaq: VRUS ... four scientific,presentations related to R7128 for the treatment ... at the 14th International Symposium on Hepatitis C,Virus ... 2007 in Glasgow,Scotland. R7128, a prodrug of PSI-6130, ...
Other Biology Technology:ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 2ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 3ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 4ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 5Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health 2Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 2Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 3Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 4Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses 5
(Date:12/16/2009)... Athletes, superstitions and rituals can help them get psyched ... anti-inflammatory drugs (NSAIDs), which many athletes gobble down before ... than good. , "These agents are treatments for the ... Stuart Warden, whose research at Indiana University focuses on ... athlete to exercise or train at a certain level, ...
(Date:12/16/2009)... 15, 2009 Signal Hill, CA Tom Bowman, ... and president of Bowman Global Change, has developed a ... fourth Intergovernmental Panel on Climate Change (IPCC) report for ... the authentic scientific information they need to make informed ... created the new format as a means to clearly ...
(Date:12/16/2009)... Dec. 1 GestureTek Inc. today ... 3.0 - a turnkey, portable, plug and ... exhibits, entertainment and touring promotions. GestureTek is ... patents in camera-enabled gesture recognition technology for ... Guaranteed for quality, the CUBE has TUV, ...
Breaking Biology News(10 mins):NSAIDs: Take 'em early and often when competing? Think again 2Bowman creates graphic translation of climate change data 2GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 3Statement of Robert Greenstein Executive Director Center on Budget and Policy Priorities on The Senate Finance Committees Health Reform Plan 59410 1Statement of Robert Greenstein Executive Director Center on Budget and Policy Priorities on The Senate Finance Committees Health Reform Plan 59410 2Statement of Robert Greenstein Executive Director Center on Budget and Policy Priorities on The Senate Finance Committees Health Reform Plan 59410 3Americans United for Lifes Statement on Finance Committee Vote 59407 1XLHealth Applauds Quality Focused Reforms in Senate Finance Committee Legislation 59404 1XLHealth Applauds Quality Focused Reforms in Senate Finance Committee Legislation 59404 2
... genetic information concerning the long-disputed origin of the ... University of La Laguna, and the International Potato ... remnants of the earliest known landraces of the ... They report their findings in the May-June 2007 ...
... Keeping at arm's length won't protect you from catching ... University of Technology which reveals airborne viruses can spread ... QUT's International Laboratory for Air Quality and Health, said ... humans only travel a metre in the air. ...
... creatures that live in the deepest parts of the Pacific ... the unlikeliest of habitats ?the carcass of a dead whale. ... sea anemone isn't so unusual. But finding one that calls ... apart. , Since the scientists who initially found these ...
Other Biology News:Spud origin controversy solved 2Spreading viruses as we breathe 2From the deep -- Researchers find new species of sea anemone 2From the deep -- Researchers find new species of sea anemone 3
... internal standard for the quantification of 5-OxoETE ... is a polyunsaturated keto acid formed by ... It stimulates cytosolic calcium levels in neutrophils ... selectively stimulates the migration and degranulation of ...
... consists of ten double-stranded RNAs, 10, 20, ... and 1,000 base pairs. The dsRNA Marker ... sizes of double-stranded RNAs. A twenty bp ... is adjusted to approximately 25 ng/µl in ...
... off-white solid. A nucleoside antibiotic that ... formation of N-glycosidic protein-carbohydrate linkages. Active ... bacteria, yeasts, fungi, and viruses. Inhibits ... on human T-lymphoblastoid cells. Also inhibits ...
... a group of enzymes involved in matrix ... metalloproteinase family ten exist in soluble form ... MT1-MMP, MT2-MMP, MT3-MMP also known as MMP14, ... domain anchoring them to the cell surface. ...
Biology Products: